Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021

JAMA. 2023 Jan 3;329(1):87-89. doi: 10.1001/jama.2022.19691.
No abstract available

Plain language summary

This study quantifies the revenue earned on all brand-name inhalers approved by the US Food and Drug Administration from 2000 to 2021 and compared earnings before and after expiration of primary patents on these products.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Industry* / economics
  • Drug Industry* / legislation & jurisprudence
  • Drugs, Generic
  • Economic Competition* / economics
  • Nebulizers and Vaporizers* / economics
  • Patents as Topic* / legislation & jurisprudence
  • United States


  • Drugs, Generic